Search

Your search keyword '"S, Noal"' showing total 2 results
Start Over Author "S, Noal" Language french
2 results on '"S, Noal"'

1. [Management of gestational trophoblastic disease]

Author

S, Noal, F, Joly, and E, Leblanc

Subjects
Adult, Antineoplastic Agents, Hydatidiform Mole, Suction, Prognosis, Chorionic Gonadotropin, Trophoblastic Tumor, Placental Site, Drug Resistance, Neoplasm, Pregnancy, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Uterine Neoplasms, Humans, Female, Choriocarcinoma, Gestational Trophoblastic Disease
Abstract

Gestational trophoblastic diseases comprise of hydatiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumor. Most of those pathologies are chemosensitive and have excellent prognosis, allowing preserving women's fertility because of the low relapse rate during further pregnancies. Physiopathological mechanisms and risk factors are now better understood. Hydatiform moles have to be treated by suction rather than curettage. Placental site trophoblastic tumors are particular chemoresistant pathologies, not secreting hCG which needs specific management. Trophoblastic tumors can be divided into two groups: a low risk group treated by monotherapy, most often by Methotrexate or actinomycine D, with survey about 100% and a high risk group treated by polychemotherapy (Etoposide, Methotrexate, actinomycine D, cyclophosphamide, Vincristine with survey of 86%. Chemorefractarory patients keep deep prognosis with 5 years survival rate of 43%, which allow development of new therapy in this indication. Measurement of hCG remains today central for supervision. A specialised management by an experimented team is essential to give patients better chance of recovery.

Published
2010

2. [Management of gestational trophoblastic disease].

Author

Noal S, Joly F, and Leblanc E

Subjects
Adult, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Choriocarcinoma diagnosis, Choriocarcinoma epidemiology, Choriocarcinoma therapy, Chorionic Gonadotropin blood, Drug Resistance, Neoplasm, Female, Gestational Trophoblastic Disease diagnosis, Gestational Trophoblastic Disease epidemiology, Humans, Hydatidiform Mole diagnosis, Hydatidiform Mole epidemiology, Hydatidiform Mole therapy, Pregnancy, Prognosis, Risk Factors, Suction, Trophoblastic Tumor, Placental Site diagnosis, Trophoblastic Tumor, Placental Site epidemiology, Trophoblastic Tumor, Placental Site therapy, Uterine Neoplasms diagnosis, Uterine Neoplasms epidemiology, Uterine Neoplasms therapy, Gestational Trophoblastic Disease therapy
Abstract

Gestational trophoblastic diseases comprise of hydatiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumor. Most of those pathologies are chemosensitive and have excellent prognosis, allowing preserving women's fertility because of the low relapse rate during further pregnancies. Physiopathological mechanisms and risk factors are now better understood. Hydatiform moles have to be treated by suction rather than curettage. Placental site trophoblastic tumors are particular chemoresistant pathologies, not secreting hCG which needs specific management. Trophoblastic tumors can be divided into two groups: a low risk group treated by monotherapy, most often by Methotrexate or actinomycine D, with survey about 100% and a high risk group treated by polychemotherapy (Etoposide, Methotrexate, actinomycine D, cyclophosphamide, Vincristine with survey of 86%. Chemorefractarory patients keep deep prognosis with 5 years survival rate of 43%, which allow development of new therapy in this indication. Measurement of hCG remains today central for supervision. A specialised management by an experimented team is essential to give patients better chance of recovery., (Copyright 2010 Elsevier Masson SAS. All rights reserved.)

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results